AstraZeneca CEO: We can absorb the impact of drug pricing deal with Trump
8.1
来源：
FiercePharma
发布时间：
2025-11-06 10:46
摘要：
AstraZeneca's CEO Pascal Soriot expressed confidence in the company's ability to meet its $80 billion revenue target by 2030, despite a recent drug pricing agreement with the Trump administration. The company reported strong sales driven by its oncology portfolio, particularly the drug Enhertu, which has shown promising phase 3 trial results for early breast cancer. Soriot emphasized the importance of attracting investment to the UK life sciences sector to support ongoing growth and innovation.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+重点关注领域符合度
business_impact
1.0分+商业影响力
scientific_rigor
1.5分+数据支撑的科学性
timeliness_innovation
1.5分+时效性与创新性
investment_perspective
2.5分+BOCG投资视角
market_value_relevance
1.0分+市场价值相关性
team_institution_background
0.1分+团队与机构背景
technical_barrier_competition
0.5分+技术壁垒与竞争格局
关键证据
AZ's CEO stated they can absorb the impact of the drug pricing deal.
Enhertu shows positive phase 3 data for early breast cancer.
AZ aims for $80 billion revenue by 2030, indicating strong growth potential.
真实性检查
否
AI评分总结
AstraZeneca's CEO Pascal Soriot expressed confidence in the company's ability to meet its $80 billion revenue target by 2030, despite a recent drug pricing agreement with the Trump administration. The company reported strong sales driven by its oncology portfolio, particularly the drug Enhertu, which has shown promising phase 3 trial results for early breast cancer. Soriot emphasized the importance of attracting investment to the UK life sciences sector to support ongoing growth and innovation.